BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23542224)

  • 1. A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT.
    Martín-Antonio B; Suarez-Lledo M; Arroyes M; Fernández-Avilés F; Martínez C; Rovira M; Espigado I; Gallardo D; Bosch A; Buño I; Martínez-Laperche C; Jiménez-Velasco A; de la Cámara R; Brunet S; Nieto JB; Urbano-Ispizua A
    Bone Marrow Transplant; 2013 Sep; 48(9):1205-11. PubMed ID: 23542224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT.
    Martín-Antonio B; Álvarez-Laderas I; Cardesa R; Márquez-Malaver F; Baez A; Carmona M; Falantes J; Suarez-Lledo M; Fernández-Avilés F; Martínez C; Rovira M; Espigado I; Urbano-Ispizua Á
    Bone Marrow Transplant; 2012 Sep; 47(9):1206-11. PubMed ID: 22231458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
    Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT.
    Chevallier P; Labopin M; Milpied N; Cornelissen JJ; Blaise D; Petersen E; Sandstedt A; Goker H; Socie G; Rocha V; Mohty M;
    Bone Marrow Transplant; 2012 Nov; 47(11):1442-7. PubMed ID: 22504932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.
    Malladi RK; Peniket AJ; Littlewood TJ; Towlson KE; Pearce R; Yin J; Cavenagh JD; Craddock C; Orchard KH; Olavarria E; McQuaker G; Collin M; Marks DI;
    Bone Marrow Transplant; 2009 May; 43(9):709-15. PubMed ID: 19029965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FcgammaRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation.
    van der Straaten HM; Fijnheer R; Nieuwenhuis HK; van de Winkel JG; Verdonck LF
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):206-12. PubMed ID: 15744239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
    Schmid C; Schleuning M; Tischer J; Holler E; Haude KH; Braess J; Haferlach C; Baurmann H; Oruzio D; Hahn J; Spiekermann K; Schlimok G; Schwerdtfeger R; Buechner T; Hiddemann W; Kolb HJ
    Bone Marrow Transplant; 2012 Jan; 47(1):46-53. PubMed ID: 21358688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation.
    Wermke M; Maiwald S; Schmelz R; Thiede C; Schetelig J; Ehninger G; Bornhäuser M; Wassmuth R
    Biol Blood Marrow Transplant; 2010 Dec; 16(12):1718-27. PubMed ID: 20541026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.
    Matthews K; Lim Z; Pearce L; Pagliuca A; Alejandro Madrigal J; Mufti GJ; Barber LD
    Br J Haematol; 2010 Jun; 149(6):879-89. PubMed ID: 20346011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
    Labouré G; Dulucq S; Labopin M; Tabrizi R; Guérin E; Pigneux A; Lafarge X; Leguay T; Bouabdallah K; Dilhuydy MS; Duclos C; Lascaux A; Marit G; Mahon FX; Boiron JM; Milpied N; Vigouroux S
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1845-50. PubMed ID: 22766221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
    Laurin D; Hannani D; Pernollet M; Moine A; Plumas J; Bensa JC; Cahn JY; Garban F
    Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
    Shimizu H; Saitoh T; Hatsumi N; Takada S; Handa H; Jimbo T; Sakura T; Miyawaki S; Nojima Y
    Leuk Res; 2013 Nov; 37(11):1477-81. PubMed ID: 24054717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
    Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
    Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience.
    Delia M; Pastore D; Mestice A; Carluccio P; Perrone T; Gaudio F; Ricco A; Sgherza N; Albano F; Specchia G
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):495-9. PubMed ID: 23200706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors.
    Elmaagacli AH; Steckel N; Ditschkowski M; Hegerfeldt Y; Ottinger H; Trenschel R; Koldehoff M; Beelen DW
    Bone Marrow Transplant; 2011 May; 46(5):702-8. PubMed ID: 20622911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
    Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up.
    Guo M; Hu KX; Liu GX; Yu CL; Qiao JH; Sun QY; Qiao JX; Dong Z; Sun WJ; Sun XD; Zuo HL; Man QH; Liu ZQ; Liu TQ; Zhao HX; Huang YJ; Wei L; Liu B; Wang J; Shen XL; Ai HS
    J Clin Oncol; 2012 Nov; 30(33):4084-90. PubMed ID: 23045576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.
    Thepot S; Zhou J; Perrot A; Robin M; Xhaard A; de Latour RP; Ades L; Ribaud P; Petropoulou AD; Porcher R; Socié G
    Leukemia; 2010 Nov; 24(11):1852-8. PubMed ID: 20827288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.